The client had a technology intended to predict when a patient can be safely removed from mechanical ventilation (MV). An RCT had been conducted and showed a reduction in MV days but not in overall ICU length of stay, and costs had not been examined.  To create compelling Value Analysis Committee (VAC) arguments, a cost of MV needed to be obtained for the “subsequent” MV days. TTi developed a protocol and additional informed consent process that was successful in permitting collection of billing data for approximately 60% of enrolled patients in both study arms. TTi’s subsequent analysis of the billing data showed a reduced cost of “subsequent” MV days ( as compared to the initial day) and even without a reduced overall ICU LOS, the cost reduction was compelling and supportive of new technology pricing.